Robert J. Hopkin, MD, on Assessing ST-920 for Fabry Disease

Video

The associate professor of clinical pediatrics at Cincinnati Children's Hospital Medical Center discussed Sangamo Therapeutics’ gene therapy, ST-920, and the phase 2 STAAR clinical trial.

“We have not had a big inflammatory reaction. In fact, no patients have required prolonged hospitalization, intensive monitoring, or medications to suppress inflammation against either the α-galactosidase A protein that's produced or against the vector that's modified from the AAV viruses. That is actually a huge deal because one of the limiting factors on implementation of gene therapy has been the triggering of the immune system and the [adverse] effects related to that.”

Fabry disease is a rare lysosomal storage disease caused by a deficiency of the enzyme α-galactosidase A (a-Gal A). Sangamo Therapeutics is currently developing an adeno-associated virus (AAV) vector-based gene therapy for the disease, isaralgagene civaparvovec (ST-920), which is intended to address needs that remain unmet with the currently available standards of care, which include enzyme replacement therapy and an oral medication.

Robert J. Hopkin, MD, an associate professor of clinical pediatrics at Cincinnati Children's Hospital Medical Center, recently presented data from the phase 1/2 STAAR clinical trial (NCT04046224), which is evaluating the safety and tolerability of ST-920 in 48 individuals in open-label, dose-ranging fashion, at the WORLDSymposium 2023, held February 22-26, in Orlando, Florida.

In an interview with CGTLive, Hopkin discussed preliminary findings from the STAAR trial, pointing out that supraphysiological levels of a-Gal A were seen in all the treated patients. He also spoke about safety, noting that none of the patients required prolonged hospitalization, intensive monitoring, or medications to suppress inflammation against a-Gal A or the AAV vector. In addition, Hopkin discussed preliminary findings from kidney biopsies, the potential implications for patients if ST-920 is approved, and future plans for further research for the gene therapy.

Recent Videos
Haydar Frangoul, MD, the medical director of pediatric hematology/oncology at Sarah Cannon Research Institute and Pediatric Transplant and Cellular Therapy Program at TriStar Centennial
David Barrett, JD, the chief executive officer of ASGCT
Georg Schett, MD, vice president research and chair of internal medicine at the University of Erlangen – Nuremberg
David Barrett, JD, the chief executive officer of ASGCT
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Caroline Diorio, MD, FRCPC, FAAP, an attending physician at the Cancer Center at Children's Hospital of Philadelphia
R. Nolan Townsend; Sandi See Tai, MD; Kim G. Johnson, MD
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Paul Melmeyer, MPP, the executive vice president of public policy & advocacy at MDA
Related Content
© 2024 MJH Life Sciences

All rights reserved.